scholarly journals COGNIZANCE FOR COVID 19 VACCINATION: CHOICE OF RECOMBINANT VIRAL VECTOR OR WHOLE VIRION INACTIVATED VACCINE

2021 ◽  
Vol 3 (4) ◽  
pp. 01-03
Author(s):  
Raghvendra Raman Mishra
Keyword(s):  
Viral Vector ◽  
Inactivated Vaccine

.

scholarly journals Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3

Vaccines ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 989
Author(s):  
Yu-Jing Fan ◽  
Kwok-Hung Chan ◽  
Ivan Fan-Ngai Hung
Keyword(s):  
Systematic Review ◽  
Adverse Events ◽  
Viral Vector ◽  
Meta Analysis ◽  
Inactivated Vaccine ◽  
Vaccine Platform ◽  
Phase 3 ◽  
Serious Adverse Events ◽  
Safety And Efficacy ◽  
Inactivated Vaccines

This systematic review and meta-analysis was conducted to compare the safety and efficacy of 2019 novel coronavirus disease (COVID-19) vaccines according to vaccine platform and severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection severity. Articles published between 24 January 2020 and 30 May 2021 were retrieved via a PubMed and EMBASE search. A total of 12 reports on phase-3 clinical trials and observational studies of COVID-19 vaccines were included in the review. In terms of vaccine safety, mRNA vaccines showed more relevance to serious adverse events than viral vector and inactivated vaccines, but no solid evidence indicated that COVID-19 vaccines directly caused serious adverse events. Serious metabolic, musculoskeletal, immune-system, and renal disorders were more common among inactivated vaccine recipients, and serious gastrointestinal complications and infections were more common among viral vector and inactivated vaccine recipients. The occurrence of serious vessel disorders was more frequent in mRNA vaccines. In terms of efficacy, two mRNA vaccine doses conferred a lesser risk of SARS-COV-2 infection (odds ratio: 0.05; 95% confidence interval: 0.02–0.13) than did vaccination with viral vector and inactivated vaccines. All vaccines protected more against symptomatic than asymptomatic cases (risk ratio, 0.11 vs. 0.34), but reduced the risk of severe SARS-COV-2 infection. The COVID-19 vaccines assessed in this study are sufficiently safe and effective. The results indicate that two mRNA vaccine doses prevent SARS-COV-2 infection most effectively, but further research is needed due to the high degree of heterogeneity among studies in this sample. Interventions should be implemented continuously to reduce the risks of infection after one vaccine dose and asymptomatic infection.

scholarly journals Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine

2021 ◽  
Author(s):  
Sitthichai Kanokudom ◽  
Suvichada Assawakosri ◽  
Nungruthai Suntronwong ◽  
Chompoonut Auphimai ◽  
Pornjarim Nilyanimit ◽  
...  
Keyword(s):  
Adverse Events ◽  
Booster Dose ◽  
Viral Vector ◽  
Significant Proportion ◽  
Booster Vaccination ◽  
T Cell Response ◽  
Healthy Adults ◽  
Inactivated Vaccine ◽  
Serious Adverse Events ◽  
Vector Vaccine

AbstractThe coronavirus disease-2019 (COVID-19) pandemic has become a severe healthcare problem worldwide since the first outbreak in late December 2019. Currently, the COVID-19 vaccine has been used in many countries, but it is still unable to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection despite patients receiving full vaccination doses. Therefore, we aimed to appraise the booster effect of the different platforms of vaccines, including inactivated vaccine (BBIBP), viral vector vaccine (AZD122), and mRNA vaccine (BNT162b2) in healthy adults who received the full dose of inactivated vaccine (CoronaVac). The booster dose was safe with no serious adverse events. Moreover, the immunogenicity indicated that the booster dose with viral vector and mRNA vaccine achieved a significant proportion of Ig anti-receptor binding domain (RBD), IgG anti-RBD, and IgA anti-S1 booster response. In contrast, inactivated vaccine achieved a lower booster response than others. Consequently, the neutralization activity of vaccinated serum had a high inhibition of over 90% against SARS-CoV-2 wild-type and their variants (B.1.1.7–alpha, B.1.351–beta, and B.1.617.2–delta). In addition, IgG anti-nucleocapsid was observed only among the group that received the BBIBP booster. Our study found a significant increase in levels of interferon gamma-secreting T-cell response after the additional viral vector or mRNA booster vaccination. This study showed that administration with either viral vector (AZD1222) or mRNA (BNT162b2) boosters in individuals with a history of two doses of inactivated vaccine (CoronaVac) obtained great immunogenicity with acceptable adverse events.

scholarly journals Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 86
Author(s):  
Sitthichai Kanokudom ◽  
Suvichada Assawakosri ◽  
Nungruthai Suntronwong ◽  
Chompoonut Auphimai ◽  
Pornjarim Nilyanimit ◽  
...  
Keyword(s):  
Adverse Events ◽  
Booster Dose ◽  
Viral Vector ◽  
Significant Proportion ◽  
Booster Vaccination ◽  
T Cell Response ◽  
Healthy Adults ◽  
Inactivated Vaccine ◽  
Serious Adverse Events ◽  
Vector Vaccine

The coronavirus disease 2019 (COVID-19) pandemic has become a severe healthcare problem worldwide since the first outbreak in late December 2019. Currently, the COVID-19 vaccine has been used in many countries, but it is still unable to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, despite patients receiving full vaccination doses. Therefore, we aimed to appraise the booster effect of the different platforms of vaccines, including inactivated vaccine (BBIBP), viral vector vaccine (AZD122), and mRNA vaccine (BNT162b2), in healthy adults who received the full dose of inactivated vaccine (CoronaVac). The booster dose was safe with no serious adverse events. Moreover, the immunogenicity indicated that the booster dose with viral vector and mRNA vaccine achieved a significant proportion of Ig anti-receptor binding domain (RBD), IgG anti-RBD, and IgA anti-S1 booster response. In contrast, inactivated vaccine achieved a lower booster response than others. Consequently, the neutralization activity of vaccinated serum had a high inhibition of over 90% against SARS-CoV-2 wild-type and their variants (B.1.1.7–alpha, B.1.351–beta, and B.1.617.2–delta). In addition, IgG anti-nucleocapsid was observed only among the group that received the BBIBP booster. Our study found a significant increase in levels of IFN-ɣ secreting T-cell response after the additional viral vector or mRNA booster vaccination. This study showed that administration with either viral vector (AZD1222) or mRNA (BNT162b2) boosters in individuals with a history of two doses of inactivated vaccine (CoronaVac) obtained great immunogenicity with acceptable adverse events.

scholarly journals Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series

RMD Open ◽  
2021 ◽  
Vol 7 (3) ◽  
pp. e002019
Author(s):  
Theerada Assawasaksakul ◽  
Seelwan Sathitratanacheewin ◽  
Preeyaporn Vichaiwattana ◽  
Nasamon Wanlapakorn ◽  
Yong Poovorawan ◽  
...  
Keyword(s):  
Immune Response ◽  
Lupus Erythematosus ◽  
Viral Vector ◽  
Case Series ◽  
Inactivated Vaccine ◽  
Vector Vaccine ◽  
The Third ◽  
Immunosuppressive Medications ◽  
Cellular Immune ◽  
Viral Vector Vaccine

Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been widely deployed in several countries for emergency use. However, the immunogenicity of the inactivated vaccine was relatively lower when compared to other vaccine types and was even more attenuated in autoimmune patients with rheumatic disease. A third-dose SARS-CoV-2 vaccination in immunosuppressed population is recommended in order to improve immune response. However, the data were limited to those initially received mRNA or viral vector SARS-CoV-2 vaccine. Thus, we aimed to describe the safety, reactogenicity and immunogenicity of patients with systemic lupus erythematosus (SLE) who received a heterogenous booster SARS-CoV-2 vaccine following the initial CoronaVac inactivated vaccine series. Our findings support that the third booster dose of mRNA or viral vector vaccine following the inactivated vaccine is well tolerated and elicited a substantial humoral and cellular immune response in inactive patients with SLE having maintenance immunosuppressive therapy without interruption of immunosuppressive medications.

1440: Novel Non-Viral Vector Using Biodegradable Thermo-Sensitive Polymer (Regel®) in the Gene Therpy of Erectile Dysfunction

2004 ◽  
Vol 171 (4S) ◽  
pp. 379-379 ◽  
Author(s):  
Ji-Kan Ryu ◽  
Hwa-Yeon Shin ◽  
Minhyung Lee ◽  
Sun U. Song ◽  
Ki-Hak Moon ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Viral Vector

Viral Vector

2020 ◽  
Author(s):  
Keyword(s):  
Viral Vector

Enhanced Stability and Controlled Delivery of MOF Encapsulated Vaccines and Their Immunogenic Response In Vivo

2018 ◽  
Author(s):  
Michael Luzuriaga ◽  
Raymond P. Welch ◽  
Madushani Dharmawardana ◽  
Candace Benjamin ◽  
Shaobo Li ◽  
...  
Keyword(s):  
Viral Vector ◽  
Controlled Delivery ◽  
Conformational Structure ◽  
Spectroscopy Analysis ◽  
Zeolitic Imidazolate Framework ◽  
Structural Conformation ◽  
Depth Study ◽  
Viral Nanoparticle

<div><div><div><p>Vaccines have an innate tendency to lose their structural conformation upon environmental and chemical stressors. A loss in conformation reduces the therapeutic ability to prevent the spread of a pathogen. Herein, we report an in-depth study of zeolitic imidazolate framework-8 (ZIF-8) and its ability to provide protection for a model viral vector against dena- turing conditions. The immunoassay and spectroscopy analysis together demonstrate enhanced thermal and chemical stability to the conformational structure of the encapsulated viral nanoparticle. The long-term biological activity of this virus-ZIF composite was investigated in animal models to further elucidate the integrity of the encapsulated virus, the bio-safety, and immunogenicity of the overall composite. Additionally, histological analysis found no observable tissue damage in the skin or vital organs in mice, following multiple subcutaneous administrations. This study shows that ZIF-based protein composites are strong candidates for improved preservation of proteinaceous drugs, are biocompatible, and capable of controlling the release and adsorption of drugs in vivo.</p></div></div></div>

Sign in / Sign up

Export Citation Format

Share Document